Navigation Links
Expanded Findings for FirstMark's Completed Clinical Study for Predicting Near-Term (2-3 Years) MI

WASHINGTON, March 20, 2012 /PRNewswire-iReach/ -- FirstMark today announced further results from the completed clinical study for the multiple biomarker cardiovascular blood test PREvent. This follows the February 16, 2012 press release announcing the completion of the clinical study demonstrating the extraordinary effectiveness of the test to predict risk of near-term (2-3 years) myocardial infarction, and death in patients with suspected or confirmed, insignificant or significant stable CAD.  The clinical study and data was well received in an oral presentation, Beyond Courage: A Possible Strategy for Identifying the Stable CAD Patient at High Risk of MI or Death, by Dr. Stephen E. Epstein, Executive Director of the Cardiovascular Research Institute, MedStar Health Research Institute, at Cardiology Grand Rounds, Washington Hospital Center, Washington, D.C., on March 20, 2012.

The study revealed superior cardiac risk information by identifying the top 5% of CAD patients at the highest risk of MI with a hazard ratio of 5.5. The data showed an annual average of 18.2% of significant CAD patients with all three biomarkers elevated experienced a myocardial infarction or death, compared to only 2.45% of significant CAD patients with all biomarkers normal.  The multiple biomarker model adds markedly to traditional risk-prediction by significantly improving C-statistics from 0.695 for base model to 0.750, distinguishing high risk from low risk subjects.

The initial results are reinforced by the additional findings, indicating very poor correlations between the levels of the test's individual biomarkers, suggesting that they are mainly independent of each other. The findings further indicate that the ability to risk strategize may improve by aggregating the results. Investigators found that regardless of whether patients were previously established into low, intermediate, or high risk clinical groups, the data from the aggregate biomarkers were able to further distinguish low and high risk patients.

"The data continues to show the test to be substantially greater than alternative markers of risk. Its ability to further distinguish patients according to specific clinical groups is beyond encouraging," said Thomas Silberg, President and CEO of GenWay Biotech.  "PREvent is a simple and inexpensive, powerful predictor of risk supported by distinguished cardiologist. The critical data and support from cardiologists shows a clear-cut clinical need for PREvent, not only for healthcare cost savings, but most importantly, saving lives through earlier detection."

About the Study
The study was based on long-term research that reveals that there are multiple factors involving components of inflammatory, thrombotic, infectious, and autoimmune pathways that contribute to the development of CAD, subsequent plaque rupture, and adverse outcomes. The research interrogated these pathways both separately and combined, utilizing HSP70, HSP60, hsCRP, FDP levels and seropositivity to CMV biomarkers. The biomarker panel was narrowed down to three markers that provide most valuable information to include hsCRP, FDP, and HSP70. A bioanalytic statistical ranking model (the Aggregate Pathway Risk) was developed that best predicts existing CAD as well as imminent MI. Of note, the investigators found poor correlations between the levels of each of the biomarkers.  This suggested, as was originally hoped by the investigators, that these biomarkers are mainly independent of each other, a finding further suggesting that by aggregating the results, the ability to risk strategize may improve.  The results were confirmatory of this.

The controlled study included blood samples from 3,800 patients admitted for cardiac catheterization. The individuals were documented from angiograms for the presence and severity of coronary artery disease. The study design included four groups of patients angiographically confirmed with insignificant or significant CAD, with MI or death and without MI or death. Each group was followed for a minimum of 1 year and a mean of 2.75 years. Groups were matched for age, gender, and cardiovascular risk factors using propensity scoring.  Of further interest, the investigators grouped patients, by clinical risk factors (age >65, diabetes, smoking history, LVEF <45%, AMI on presentation, and coronary stenosis ≥50%).  They found that regardless of whether patients were in the low, intermediate, or high risk clinical groups, the biomarkers were able to further distinguish low and high risk patients within each of the clinical risk groups.  For example, in the high risk clinical group patients with no biomarker positive had a 4 year event-free survival of about 75%, whereas the event-free survival fell to nearly 40% in those patients with ≥2 biomarkers positive.

Additional study details are provided at:

About FirstMark
FirstMark is a division of GenWay Biotech, Inc. The FirstMark division is focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. Headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area. For additional information please visit

Media Contact: Deborah Moore, GenWay Biotech Inc., 858-458-0866,

News distributed by PR Newswire iReach:

SOURCE GenWay Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round
2. Medical Malpractice Insurance Company- Healthcare Providers Insurance Exchange (HPIX) has Expanded its Presence in New Jersey, Opens New Office
3. NAFG Announces Expanded International Surrogacy and Egg Donation Program
4. Oxygen Healthcare (O2h) Announces Expanded Chemistry Collaboration With Heptares Therapeutics
5. MS Noise™ Expanded Product Line Increases Lab Productivity by Significantly Reducing Noise
6. Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin
7. NeurogesX to Pursue Expanded U.S. Label for Qutenza® (capsaicin) 8% Patch in HIV-Associated Neuropathy
8. Expanded Lipoprotein Testing, VAP® Cholesterol Test Discussed at National Lipid Association Summer Clinical Lipid Update
9. EMEA Validates Cell Therapeutics, Inc.s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
10. S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors
11. China Yongxin Pharmaceuticals Opened Three New Stores in 2009 and Expanded Customer Base
Post Your Comments:
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... June 27, 2016   Ginkgo Bioworks , a ... engineering, was today awarded as one of the ... the world,s most innovative companies. Ginkgo Bioworks is ... the real world in the nutrition, health and ... directly with customers including Fortune 500 companies to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
Breaking Biology Technology:
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
Breaking Biology News(10 mins):